ACTU Stock Forecast & Price Target

Actuate Therapeutics is a clinical stage biopharmaceutical company with a strong fundamental outlook due to the potential of its lead product, elraglusib, a GSK-3B inhibitor that has shown positive efficacy in a Phase 2 trial with a primary endpoint of overall survival. The company has a diversified pipeline and potential for conditional marketing authorization in the EU, which could accelerate market entry. Despite regulatory risks, the company has a strong financial position with a projected rNPV of $656M and net cash of $13.1M, leading to a 12-month price target of $15. The potential for a strategic partnership or non-dilutive capital raise could further increase the upside potential for the stock.

Actuate Therapeutics is a clinical stage biopharmaceutical company with a potentially promising therapy in elraglusib, but their financials show no current revenue and a projected net loss for the next year. Additionally, the potential for long-term clinical benefit in the mPDAC population and expansion into other indications through an oral formulation may be promising, but the uncertainty of future success and limited funding may pose a significant risk for investors. Without significant revenue or funding, the company may struggle to support continued operations and its financial outlook remains negative.